WO2012046993A2 - Composition for preventing or treating dementia containing prunus mume extract - Google Patents
Composition for preventing or treating dementia containing prunus mume extract Download PDFInfo
- Publication number
- WO2012046993A2 WO2012046993A2 PCT/KR2011/007314 KR2011007314W WO2012046993A2 WO 2012046993 A2 WO2012046993 A2 WO 2012046993A2 KR 2011007314 W KR2011007314 W KR 2011007314W WO 2012046993 A2 WO2012046993 A2 WO 2012046993A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dementia
- extract
- preventing
- group
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- composition for the prevention or treatment of dementia containing the ume extract
- the present invention relates to a composition for the prevention or treatment of dementia containing a mae extract.
- Dementia is dementia when one or more of four, including memory disorders, disorientation, loss of computing power, and changes in personality and emotions, are memory impaired to a degree that impairs normal daily life in occupation, social life, and interpersonal relationships. Diagnosed with. Dementia is a pathological condition that should be distinguished from normal aging and, depending on its cause, Alzheimer's disease, vascular dementia, other alcoholism, trauma and Parkinson's disease. It is distinguished by.
- vascular dementia is mainly caused by cerebral infarction or stroke, and it is known that brain cells around the affected area are damaged and cause symptoms such as memory loss.
- Alzheimer's dementia is a degenerative brain disease caused by brain cell destruction, and progresses slowly with symptoms such as memory loss, personality changes, and decreased thinking ability, but most patients die of pneumonia within 8 to 10 years. It is known. Recent epidemiologic studies have reported that risk factors for cerebrovascular diseases such as hypertension, diabetes, hyperlipidemia, and heart disease increase the incidence of Alzheimer's as well as vascular dementia.
- the treatment of dementia by the mechanism of action according to the lesion and cause includes acetylcholine esterase inhibitor crab, antioxidant, anti-inflammatory agent, hormonal agent, cholesterol lowering agent and beta-amyloid blocker.
- the acetylcholine esterase is not damaged By partially increasing the activity of the cholinergic nervous system that is left to restore partial cognitive impairment.
- Frutus Mume is a plum tree (/ T / yjiAS The raw fruit is placed in a jar, covered with a lid, and then sutured and heated until it becomes black, which stops old coughs and sputum, is good for quenching thirst, and the nervousness of the chest becomes stuffy and indigestible. It is said to be good for use.
- the ume has been known to have an immune function, antibacterial action, hypoglycemic effect, the conventional research on the efficacy of maeja the inhibitory effect of the uraase activity of Helicobacter Philophyll containing the mae extract (Korean Patent Publication No. 2006-0040254) , Analgesic action of -0-D-glucose isolated from omega extract (Korean Patent Publication No. 1998- 0043925), blood circulation improving composition containing omega extract or fractions thereof as an active ingredient (Korean Patent Publication No. 2010 -0042414).
- the present inventors have confirmed that the ume extract has an excellent effect on normalizing memory capacity and normalizing hippocampal damage in a vascular dementia animal model, thereby confirming that it can be usefully used as an active ingredient in a composition for preventing or treating dementia.
- the invention was completed.
- the present invention provides a pharmaceutical composition for the prevention or treatment of dementia containing the fruit extract (Frutus Mume) as an active ingredient.
- the present invention provides a composition for the prevention or improvement of health functional foods containing dementia containing the fruit extract (Frutus Mume) as an active ingredient.
- the present invention provides a method for treating dementia comprising administering a pharmaceutically effective amount of a mae extract to an individual suffering from dementia.
- the present invention provides a method for preventing dementia comprising administering to the individual a pharmaceutically effective amount of a mae extract.
- the present invention also provides the use of a berry extract for the manufacture of a medicament for the treatment or prevention of dementia.
- the present invention provides the use of a mae extract for the manufacture of dietary supplements for the prevention or improvement of dementia.
- a mae extract for the manufacture of dietary supplements for the prevention or improvement of dementia.
- the present invention provides a pharmaceutical composition for preventing or treating dementia, containing the mae extract as an active ingredient.
- the mae extract of the present invention is a pharmaceutical composition for preventing or treating dementia, containing the mae extract as an active ingredient.
- the extract of step 1) is preferably prepared by a manufacturing method comprising the step of concentrating and drying under reduced pressure to obtain a dry powder, but is not limited to the above method.
- step 1) the plums are put in a jar, put the raw fruit of the plum tree, cover with a lid, and then sutured with mud and heated until black, can be used without limitation, such as grown or commercially available. Can be.
- the water of step 1) is characterized by using distilled water, alcohol is characterized in that using a lower alcohol of d to C 4 , the lower alcohol is characterized in that ethanol or methane.
- organic matter is characterized by using distilled water, alcohol is characterized in that using a lower alcohol of d to C 4 , the lower alcohol is characterized in that ethanol or methane.
- the solvent is preferably extracted by adding 2 to 10 times the amount of mae, more preferably 3 to 4 times to extract, but not always limited thereto.
- Extraction method using a conventional extraction method in the art such as hot water extraction, steam extraction, reflux extraction, filtration or ultrasonic extraction, it is preferable to extract the ultrasonic wave or hot water, more preferably ultrasonic cogeneration extraction is not limited thereto.
- the silver content of the solvent at the time of extraction is preferably 20 ° C-100 ° C, more preferably 95 ° C, but is not limited thereto.
- the extraction time is preferably 1 hour to 24 hours, more preferably 2 hours is not limited thereto.
- the number of extraction is preferably 1 to 5 times, more preferably 3 times repeated extraction is not limited thereto.
- the vacuum concentration and drying process of step 2) may be performed by a conventional method used in the art.
- the dementia may be vascular dementia or Alzheimer's dementia, preferably vascular dementia, but is not limited thereto.
- the experimental animal is a whistle rat
- chronic cerebral hypoperfusion is bilateral common carotid artery occlusion, 2V0, Hereinafter referred to as "brain injury (BCCAo)" (Wakita et al., 1994).
- BCCAo brain injury
- the oral extract concentration of the mae extract according to the invention was determined as low concentration (100 mg / kg), medium concentration (200 mg / kg) and high concentration (400 mg / kg).
- Chotosan 300 mg / kg
- the experiment was designed by applying a total of six groups to the control drug administration group, the sham procedure group and the experimental group.
- the trial of administering the ume extract to the vascular dementia animal model for 3 weeks (training trial, obtained in water) The ability to visit the marker barrel).
- the mae extract extract group showed a learning disorder of hippocampus-dependent learning compared to the brain injury group (BCCAo) (FIG. 1).
- the simulated group performed better underwater memory storage than the brain injury group (BCCAo).
- the mae extract administration group treated with the mae extract of Example 1 the 200 rag / kg administration group of the extract of Example 1 showed a good performance of almost the control level.
- the mae extract according to the present invention can effectively normalize memory capacity, and thus may be usefully used for preventing or treating dementia.
- the brain injury group (BCCAo) does not remember the location of the platform significantly more than the simulated group.
- FIG. 4a is a Western blotting results
- Fig. 4b is a Western blow normalization of hippocampal damage ohmae extract according to the present invention as a graph showing the results plated (ERK (Extracel hilar signal -regulated kinase ; EK) normalization of phosphorylation, increased ChAT ) It is a graph showing the effect.
- Figure 4c is a Western blotting result
- Figure 4d is a graph showing the Western blotting result is a graph showing the effect of normalization of hippocampal damage (normalization of NF-kappa B) of the mae extract according to the present invention.
- the brain injury group (BCCAo) showed no difference in ERK levels compared to the sham treatment group, but the ERK phosphorylation was significantly higher.
- the level of ERK phosphorylation was significantly decreased by the treatment of the ume extract (p ⁇ 0.05).
- ChAT choline acetyltransferase, an enzyme used for the production of acetylcholine
- the level of NF-kappa B was normalized by the ume extract treatment.
- histological marker test /> ⁇ was performed.
- a monoclonal antibody Iba-1 (ionized calcium-binding adapter molecule) was used to detect microglia cells in the hippocampus. This Iba-1 expresses in microglia cells and microphases.
- Figure 5 shows the change in the number of microglia cells in the hippocampus following treatment with ume extract. 5A is a result of tissue immunostaining, and FIG. 5B is a graph showing the results of tissue immunostaining.
- the brain injury group (BCCAo) had significantly higher microglia cell counts than the simulated group.
- the microglia cell expression was significantly decreased by 200 mg / kg treatment of ume extract ⁇ 0.05).
- the weight change was measured during the experiment to determine the toxicity of the mae extract according to the present invention.
- Body weight due to brain injury BCCAo
- BCCAo brain injury
- overall administration of the mae extract did not affect the weight change (FIG. 6). Therefore, the extract according to the present invention does not show toxicity and can be usefully used for preventing or treating dementia.
- the mae extract according to the present invention can effectively normalize the damaged hippocampus, and can be usefully used for preventing or treating dementia since there is no toxicity.
- the prophylactic or therapeutic compositions can be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, oral formulations, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods.
- Solid preparations for oral administration include powders, granules, tablets, capsules, soft capsules, and pills.
- Oral liquid preparations include suspending agents, liquid solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
- Preparations for parenteral administration may be in the form of powders, granules, tablets, capsules, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, syrups, suppositories, aerosols, etc. It can be used in the formulation, preferably to prepare a skin external pharmaceutical composition of cream, gel, patch, spray, ointment, warning, lotion, linen, pasta or cataplasma, It is not limited to this.
- the non-aqueous solvent and suspending agent propylene glycol, vegetable oil such as polyethylene glycol, and injectable ester such as ethyl oleate may be used.
- a base of suppositories witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
- the prophylactic or therapeutic composition according to the present invention may further include a carrier, excipient, disintegrant, sweetener, lubricant, flavoring agent and diluent which are commonly used.
- the carrier, excipient, and diluent may include lactose, dextrose, sucrose, solbi, manny, xili, erysri, maltitol, starch, acacia rubber, alginate, gelatin, and scabbard.
- the disintegrants include sodium starch glycolate, crospovidone, croscarmellose sodium, alginic acid, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, chitosan, guar gum, low-substituted hydroxypropyl cellulose, magnesium Aluminum silicate, polyacrylic potassium and the like.
- the prophylactic or therapeutic composition according to the present invention may further include a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additive includes starch, gelatinized starch, microcrystalline salose, lactose, povidone, colo Calcium Dioxide Hydrogen Phosphate, Lactose, Mannitle, Peel, Arabian Rubber, Pregelatinized Starch, Corn Starch, Powdered Cellulose, Hydroxypropyl Cellulose, Opadry, Sodium Starch Glycolate, Carnauba Lead, Synthesis Aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, white sugar, textose, sorbide, talc and the like can be used.
- the pharmaceutically acceptable additive according to the present invention is preferably included 0.1 to 90 parts by weight based on the pharmaceutical composition.
- the prophylactic or therapeutic composition of the present invention may further contain one or more active ingredients exhibiting the same or similar functions in addition to the above components.
- the composition of the present invention comprises 0.0001 to 10% by weight, preferably 0.001 to 1% by weight, based on the total weight of the composition.
- the prophylactic or therapeutic composition of the present invention can be administered orally or parenterally, and when parenteral administration is selected for external skin or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection or intrathoracic injection injection method. It is preferable.
- the present invention comprises a mae extract as an active ingredient
- the ume extract is a composition for preventing or treating dementia It can be prepared by the same method as the extract.
- the dementia may be vascular dementia or Alzheimer's dementia, preferably vascular dementia, but is not limited thereto.
- the mae extract of the present invention may be added to food as it is, or used with other foods or food ingredients, and may be appropriately used according to a conventional method.
- the mixed amount of the active ingredient can be suitably determined according to the purpose of use (prevention or improvement).
- the composition of the present invention is added in an amount of 0.2 to 20% by weight, preferably 0.24 to 10% by weight, based on the raw materials.
- the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.
- the health functional food of the present invention may contain various flavors or natural carbohydrates as additional ingredients.
- the above-mentioned natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xyl, sorbitol and erythritol.
- natural sweeteners such as taumartin, stevia extract, synthetic sweeteners such as saccharin, aspartame, and the like can be used.
- the ratio of the natural carbohydrate is preferably selected in the range of 0.01 to 0.04 parts by weight, preferably about 0.02 to 0.03 parts by weight, per 100 parts by weight of the health food of the present invention.
- dietary supplement there is no particular limitation on the type of dietary supplement.
- foods to which the substance may be added include drinks, meat, sausages, breads, biscuits, rice cakes, chocolates, candy, snacks, confectionery, pizza, ramen, other noodles, 3 ⁇ 4, ice creams including ice cream, and various soups.
- Beverages, alcoholic beverages and vitamin complexes and includes all healthy foods in the usual sense.
- the health functional food of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols. , Used for soda It may contain a carbonating agent.
- the health functional food of the present invention may contain a flesh for producing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The ratio of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.
- the present invention also provides a method for treating dementia, comprising administering a pharmaceutically effective amount of the mae extract to an individual suffering from dementia.
- the present invention provides a method for preventing dementia comprising administering to the subject a pharmaceutically effective amount of the mae extract.
- the dementia may be vascular dementia or Alzheimer's dementia.
- the subject can be any animal, including humans.
- the ume extract is an active ingredient exhibiting the same ' or similar function further
- It can contain 1 or more types.
- the administration may be administered orally, or parenterally by subcutaneous injection, intravenous injection or intramuscular injection, and may be used in the form of a general pharmaceutical formulation.
- the omega extract according to the present invention has an effect of normalizing hippocampal damage induced by chronic vascular brain injury (normalizing ERK phosphorylation, increasing CMT, normalizing NF-kappa B) and improving spatial memory in vascular dementia animal model. It can be usefully used for the prevention or treatment of diseases associated with vascular brain injury, such as [Brief Description of Drawings]
- FIG. 2 shows the degree of stay in the test platform area in two probe trials (% Time in Target Counter).
- a graph represented by) is a graph showing the effect of normalizing the spatial memory capacity of the mae extract according to the present invention.
- FIG. 3 shows the average swimming speed (m / sec) according to the number of sessions. This graph shows that there is no movement disorder due to brain injury.
- BCCAo + Vehicle Brain injury BCCAo + Choto-san 300's group treated with 300 mg / kg of Choto-san in the brain injury group
- FIG. 4a is a Western blotting result and Figure 4b is a graph showing the Western blotting result as a falsification according to the present invention It is a graph showing the effect of normalization of hippocampal damage of the extract (normalization of ERK (Extracel hilar signal-regulated kinase; ERK) phosphorylation, ChAT increase).
- ERK Extracel hilar signal-regulated kinase
- FIG. 4c is a Western blotting result
- Figure 4d is a graph showing the Western blotting result is a falcon according to the present invention It is a graph showing the effect of normalizing hippocampal damage of the extracts (NF-kappa B levels normalized).
- FIG. 5a is an immunohistostaining result and FIG. 5b is a graph showing the results of immunohistostaining.
- FIG. 6 is a graph showing the weight change by the treatment of the mae extract.
- the omae used in this experiment was purchased from Gwangmyeongdang (Ulsan Material) and was used in the experiment after confirming the external form by the Korean Herbal Medicine Quality Inspection Team of Korea Institute of Oriental Medicine.
- Dried water (2 kg) was placed in an ultrasonic co-extractor (0M30-EP, SONIMEDI) and distilled water 8 I It was added and extracted for 120 minutes at 95 ° C.
- the extract was put in a dry liquid dryer (EXDRYER, S0NIMEDI Co., Ltd.) and dried at -95 kPa or less at 80 ° C. for 48 hours to prepare a mae extract (yield 16.225%).
- EXDRYER dry liquid dryer
- Vascular dementia animal model and drug oral administration (/ ⁇ VIVO)
- the experimental animals used in this experiment were 12-week-old 350-400 g of Wister rats. After visual examination of the experimental animals, the appearance was examined visually, and then general symptoms were observed during the 7-day purifying period, and healthy animals were selected.
- the breeding environment has a temperature of 23 ⁇ 3 ° C, a relative humidity of 50 ⁇ 10%, a ventilation frequency of 12 16 hours per hour, lighting of a 12-hour contrast cycle (lighting up at 7:00, lighting out at 19:00), illuminance. was adjusted to 150 ⁇ 300 Lx to maintain a constant breeding environment conditions for the entire test period.
- the experimental group was orally administered five days after BCCAo treatment of ume extract in Wistar rats. There are a total of 6 groups and each group Experimented with 16 stars. The preliminary results show that about 40% of mice have visual impairments, so blind and non-blind groups can be tested using a Shuttle Box one week before the behavioral test, i. Rats in the blind group were orally administered for 42 days, and mice in the non-blind group tested for memory were orally administered for 42 days.
- Table 1 shows the verification of cognitive function.
- Oral extract concentration of omae extract according to the present invention was determined to be low concentration (100 mg / kg), medium concentration (200 mg / kg) and high concentration (400 mg / kg), Chotosan (300 mg / kg) control drug
- the experiment was designed by applying a total of six groups to the administration group, the simulation procedure group, and the experimental group.
- Behavioral tests were performed through a water maze test. Place partitions in all directions so that light does not shine in the water, and mark the water at a temperature of 26 ⁇ 2 ° C in a round water tank (183 cm in diameter and 58 cm in height). Fill it up to about 2 cm and add color so that the bottom is not visible. Markers are also attached to the divider and to specific locations to provide clues for rats to visit the marker bins. It was designed to locate marker containers (12 c in diameter and 33.5 cm in height) in specific places in the water tank and to swim to find the surviving marker bottles.
- the time, distance, and speed of the rats from the time of acquisition to the marker can be measured and used as markers of memory.
- the mae extract of Example 1 was administered for 3 weeks and a training trial (training trial, the ability to obtain a marker bottle by water) was conducted. Rather than measuring after training, the movement of rats is simultaneously tracked to measure time and distance. Therefore, the time and distance that are shortened every day are compared between groups. In other words, the faster and shorter the time and distance, the better the learning. Training attempts were conducted eight times a day (from 9:00 am), using a total of eight days of morning time.
- the spatial memory capacity was evaluated by long-term oral administration of the ume extract of Example 1, and the cognitive ability evaluation (spatial memory capacity) was trained four times a day and was trained over a total of eight days. Days after the last trial. In addition, one week later, cued training was performed (6 times a day).
- the mae extract extract group showed a learning disorder of hippocampus-dependent learning compared to the brain injury group (BCCAo) (FIG. 1).
- the simulated group performed better underwater memory storage than the brain injury group (BCCAo).
- the mae extract administration group treated with the mae extract of Example 1 the 200 nig / kg administration group of the extract of Example 1 showed a good performance of almost the control level.
- the mae extract according to the present invention can effectively normalize memory capacity, and thus may be usefully used for preventing or treating dementia.
- the brain injury (BCCAo) and 200 rag / kg OH extracts significantly reduced swimming in the area at about five times the size of the polyp compared to the sham treatment group 0.014 , first probe trial).
- the mae extract according to the present invention is shown to enhance memory capacity.
- the average swimming speed did not show any difference among the groups during the underwater aquatic training (FIG. 3). This indicates no movement disorder in all groups.
- Table 2 shows the results of cued training. By blacking out the color of the platform and placing it on the surface, rats can easily see the platform. Individuals with disabilities on this task may exhibit motor skills or striatum acquisition disorders. Six cue training sessions showed differences between groups. The group receiving 200 mg / kg of falcon showed almost the same performance level as the simulated group.
- Brain tissues of fast-moving rats were thawed on ice and cold protein extracts (1 M Tris [pH7.5], 0.5 M EDTA, 1 M KC1 , R2011 / 007314
- Glycerol 100% 100 nM Di thiothrei tol, proteinase inhibitor was added to homogenize for 8 minutes.
- the tissue was ultracentrifuged (14,000 rpm, 4 ° C., vacuum) for 1 hour and the liquid collected in the upper part of the test tube. After analyzing the amount of each protein by the Bradford method, the protein was stabilized with a sample buffer.
- Each protein sample was electrophoresed at 100 V through SDS-polyacrylamide gel, and the protein bands were transferred to a polyvinylidene fluoride (PVDF) membrane for 1 hour using a transfer unit at 100 V and 400 mA. Moved. Then washed once with TBST and blocked with 5% skim milk (1 hour, room temperature).
- PVDF polyvinylidene fluoride
- Anti-rabbit IgG secondary antibody (Amersham) was treated with 1: 5000 in 5% skim milk and treated at room temperature for 1 hour. Finally, three TBST washes (10 min / time) were followed by reaction with ECL solution and developed on the film.
- Figure 4 shows the ERK (Extracel hilar signal-regulated kinase; ERK) phosphorylation, ChAT (choline acetyl transferase; ChAT), I ⁇ B (Inhibi tor of ⁇ ), NF-kappa B (nuclear factor kappa-1) ight -chain-enhancer of activated B cells; NF-kappa B).
- Figure 4a is a Western blotting results and Figure 4b is a graph showing the Western blotting results of the normalization of hippocampal damage (ERK (Extracel hilar signal -regulated kinase; ERK) phosphorylation normalization, ChAT increase) effect of the ume extract according to the present invention
- ERK Extracel hilar signal -regulated kinase
- FIG 4d is a graph showing the result of Western blotting is a graph showing the effect of normalization of hippocampal damage (normalization of NF-kappa B) of the mae extract according to the present invention ⁇ brain injury group (BCCAo) showed no difference in the level of ERK compared to the simulated group.
- ERK Extracel hilar signal -regulated kinase
- ERK phosphorylation was quite high.
- the level of ERK phosphorylation was significantly decreased by the treatment of the ume extract (p ⁇ 0.05).
- Chat choline acetyltransferase, an enzyme used for the production of acetylcholine
- BCCAo brain injury group
- the level of NF-kappa B was normalized by the mae extract extract treatment.
- the mae extract according to the present invention can effectively normalize the damaged hippocampus and thus can be usefully used for preventing or treating dementia.
- mice used for histological markers were 4% paraformaldehyde mixed with 0.01 M PBS after anesthesia with a mixture of ketamine HC1 (30 mg / kg) and xylazine (2.5 mg / kg). (paraformaldehyde; PFA).
- the brain was removed and postfixed in 4% PFA (2 days), cryoprotected in PBS containing 30% sucrose (48 hours), and the tissue was protected from the cold. , Frozen in powdered dry ice and stored at -70 ° C until experiment.
- Perfused brain tissues were excised to a thickness of 40 with a microtome and stored in 4 ° C PBS.
- the monoclonal antibody Iba-1 (ionized calcium-binding adapter molecule) was used to detect the microglia cells of the hippocampus. This Iba-1 is expressed in microglia cells and microphases.
- resistant peroxidase in the free floating section was quenched through 30 minutes of incubation in PBS with 3% 3/4 2 /10% MeOH.
- the tissues were then incubated for 1 hour at room temperature in 0.3% Triton-XOO (PBS-TS) PBS with 10% serum.
- PBS-TS Triton-XOO
- the tissues were then incubated with Iba-1 antibody in 4 ° C 3% PBS-TS solution (solution) for about 12 hours.
- the tissues were then isolated from horse anti-mouse antibody (Vector; 1: 200) and ExtrAvidin peroxidase conjugate (Sigma Aldrich; 1: 1000), respectively. Incubated for one hour. Finally, the tissues were reacted with the Vector SG substrate kit (Sigma Aldrich) for peroxidase and dried on a slide coated with resin for a week. Dried tissue on the slide is combined with the slide cover by a permount reagent. By quantifying the reacted microglia through statistical analysis, the Iba-1 antibody found that the hippocampus of six brain sections per animal contained microglia.
- FIG. 5 shows the change in the number of microglia cells in the hippocampus following treatment with ume extract.
- 5A is a result of tissue immunostaining
- FIG. 5B is a graph showing the results of tissue immunostaining.
- the brain injury group (BCCAo) had significantly higher microglia cell counts than the simulated group.
- the microglia cell expression was significantly decreased by 200 mg / kg treatment of ume extract ⁇ 0.05).
- the mae extract according to the present invention can effectively normalize the damaged hippocampus and thus can be usefully used for preventing or treating dementia.
- Weight change was measured during the experiment to determine the toxicity of the mae extract according to the present invention.
- Figure 6 shows the weight change by the treatment of mae extract.
- Body weight due to brain injury BCCAo
- BCCAo brain injury
- the extract according to the present invention does not exhibit toxicity and may be usefully used for preventing or treating dementia.
- the preparation examples for the compositions of the present invention are illustrated below.
- the above ingredients were mixed and layered in an airtight cloth to prepare a powder.
- tablets were prepared by tableting according to a conventional method for preparing tablets.
- the capsule was prepared by layering the gelatine capsules according to the conventional method for producing capsules.
- Brown rice, barley, rice, and jujube were alphanized by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh.
- Black beans and black sesame perilla were also roasted by a known method and then dried to prepare a powder having a particle size of 60 mesh.
- Ultrasonic cogeneration extract of five medium of the present invention was concentrated under reduced pressure in a vacuum concentrator, dried by spraying and drying with a hot air dryer, and ground to a particle size of 60 mesh by a grinder to obtain a dry powder.
- the dry powders of the ultrasonic cogeneration extracts of the grains, seeds and hawks prepared above were formulated in the following ratios.
- Cereals (30 parts by weight brown rice, 15 parts by weight brittle, 20 parts by weight of barley) ,
- Seeds (7 parts by weight perilla, 8 parts by weight black beans, 7 parts by weight black sesame seeds),
- Ultrasonic Cogeneration Extract of Substances such as Liquid Fructose (0.5 wt%), Loligosaccharide (2 wt%), Sugar (2 wt%), Salt (0.5 wt%), Water (75 wt 3 ⁇ 4 ») and Substances of the Invention 5 g of homogeneously blended and sterilized immediately and then packaged in a small packaging container such as glass bottles, plastic bottles to prepare a healthy beverage.
- Health promotion fruit juice was prepared by adding 1 g of ultrasonic co-extraction extract of the ume of the present invention to 1,000 apples or grape juice.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201180058231.2A CN103237556B (en) | 2010-10-04 | 2011-10-04 | Comprise the compositions for preventing or treat dementia of Fructus Mume extract |
US13/996,319 US9814749B2 (en) | 2010-10-04 | 2011-10-04 | Composition for preventing or treating dementia containing prunus mume extract |
JP2013532720A JP5688467B2 (en) | 2010-10-04 | 2011-10-04 | A composition for preventing or treating dementia (dementia), containing a ume extract |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0096417 | 2010-10-04 | ||
KR20100096417 | 2010-10-04 | ||
KR1020110100670A KR101434464B1 (en) | 2010-10-04 | 2011-10-04 | Composition comprising extracts of Fructus Mume for prevention or treatment of dementia |
KR10-2011-0100670 | 2011-10-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012046993A2 true WO2012046993A2 (en) | 2012-04-12 |
WO2012046993A3 WO2012046993A3 (en) | 2012-07-19 |
Family
ID=45928202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/007314 WO2012046993A2 (en) | 2010-10-04 | 2011-10-04 | Composition for preventing or treating dementia containing prunus mume extract |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012046993A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040002423A1 (en) * | 2000-04-10 | 2004-01-01 | Hiromu Ohnogi | Remedies |
KR20050035906A (en) * | 2003-10-07 | 2005-04-20 | 롯데제과주식회사 | The modified sagunza-tang which is effective on improvement of anti-stress and brain function |
US20060257351A1 (en) * | 2001-10-09 | 2006-11-16 | Fancel Corporation | Compositions for potentiating glutatthione |
-
2011
- 2011-10-04 WO PCT/KR2011/007314 patent/WO2012046993A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040002423A1 (en) * | 2000-04-10 | 2004-01-01 | Hiromu Ohnogi | Remedies |
US20060257351A1 (en) * | 2001-10-09 | 2006-11-16 | Fancel Corporation | Compositions for potentiating glutatthione |
KR20050035906A (en) * | 2003-10-07 | 2005-04-20 | 롯데제과주식회사 | The modified sagunza-tang which is effective on improvement of anti-stress and brain function |
Also Published As
Publication number | Publication date |
---|---|
WO2012046993A3 (en) | 2012-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101434464B1 (en) | Composition comprising extracts of Fructus Mume for prevention or treatment of dementia | |
EP3560506A1 (en) | Pharmaceutical composition comprising indigo pulverata levis extract or fraction thereof as effective ingredient for preventing or treating inflammatory bowel disease | |
CN105338993A (en) | Composition for preventing, relieving or treating colitis, containing complex extracts | |
KR20090050295A (en) | A composition for the prevention and treatment of edema or dermatitis containing glehnia littoralis fr. schmidt et miquel extract as an active ingredient | |
CN103313717A (en) | Composition containing styraxlignolide A or the aglycone thereof as an active ingredient for preventing or treating asthma | |
KR101226824B1 (en) | A composition comprising the extract of Sorghum bicolor L. Moench as an active ingredient for preventing and treating inflammatory disease | |
US9737583B2 (en) | Composition for prevention or treatment of acute renal failure including herbal extract or fraction thereof as active ingredient | |
EP3025721B1 (en) | Pharmaceutical composition for preventing or treating asthma comprising pistacia weinmannifolia j. poiss. ex franch extract or fraction thereof | |
KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
KR20200053016A (en) | Pharnaceutical composition for prevention or treatment of diabetes comprising the mixed extract of vegetable natural products having the effect on removal of swelling and health functional food for prevention or improvement of diabetes comprising the same | |
KR101651924B1 (en) | Composition for curing asthma containing extract of salvia plebeia leaft and extract of fermented allium hookeri root | |
KR102203657B1 (en) | A composition comprising the complex extract for antiobesity of women | |
KR102122408B1 (en) | Composition for preventing, ameliorating or treating andropause syndrome comprising roasted Glycyrrhiza uralensis extract as effective component | |
KR20120060002A (en) | A composition for prevention and treatment of dementia or Parkinson's disease comprising extracts of Morus alba or Lycium chinense, or mixture thereof as an active ingredient | |
WO2012046993A2 (en) | Composition for preventing or treating dementia containing prunus mume extract | |
KR101938055B1 (en) | A composition for treating, improving and preventing of artheriosclerosis comprising Gracilariopsis chorda ohmi extract or Gracilariopsis chorda ohmi fraction | |
EP2992890B1 (en) | Pharmaceutical composition for treatment of inflammatory bowel disease | |
KR101742102B1 (en) | Composition for preventing, improviong or treating disease caused by side effect of anticancer agent comprising Trichosanthes kirilowii Maximowicz extract as effective component | |
KR102561751B1 (en) | Composition for prevention, treatment or improvement of muscle disease comprising BLB301, complex extract of black raspberry and Phlomis umbrosa | |
KR102158661B1 (en) | Composition for preventing, ameliorating and treating inflammatory diseases comprising extract of undried immature astrigent persimmon of miyrangbansi as effective component | |
KR101712889B1 (en) | Pharmaceutical composition comprising Zingiber mioga extracts or its fractions for prevention and treatment of neurodegenerative disorders as an active ingredient | |
KR102116744B1 (en) | Composition for promoting differentiation of muscle cells containing Allium hookeri extract as effective component | |
KR20230096887A (en) | Composition for preventing, ameliorating or treating skin disease comprising Securinega suffruticosa extract as effective component | |
KR20050107362A (en) | Health improving food containing an extract of the root bark of ulmus davidiana var | |
KR20230161339A (en) | Composition for prevention, improvement or treatment of arthritis and joint pain comprising Ribes fasciculatum var. chinense extract as effective component |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180058231.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11830878 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase in: |
Ref document number: 2013532720 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13996319 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11830878 Country of ref document: EP Kind code of ref document: A2 |